Bionomics Limited (BNOX)
- Previous Close
0.9663 - Open
0.9900 - Bid 0.7000 x 200
- Ask 1.2300 x 200
- Day's Range
0.9336 - 1.0000 - 52 Week Range
0.8700 - 6.4100 - Volume
43,732 - Avg. Volume
131,603 - Market Cap (intraday)
10.693M - Beta (5Y Monthly) -0.09
- PE Ratio (TTM)
-- - EPS (TTM)
-2.3400 - Earnings Date Apr 29, 2024 - May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
www.bionomics.com.auRecent News: BNOX
Performance Overview: BNOX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BNOX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BNOX
Valuation Measures
Market Cap
10.69M
Enterprise Value
-863.03k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
569.68
Price/Book (mrq)
0.50
Enterprise Value/Revenue
-39.15
Enterprise Value/EBITDA
0.03
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.13%
Return on Equity (ttm)
-80.80%
Revenue (ttm)
661.98k
Net Income Avi to Common (ttm)
-31.01M
Diluted EPS (ttm)
-2.3400
Balance Sheet and Cash Flow
Total Cash (mrq)
14.87M
Total Debt/Equity (mrq)
5.41%
Levered Free Cash Flow (ttm)
-13.58M